A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia.

Investigator: Andrew Billnitzer

Study Coordinator:

Status: Enrolling

ClinicalTrials.gov Number: NCT03701399

Phone:

Protocol Number: Pro00020426

Description

The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).